Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope; Peter A. Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; Thomas J. Walsh; David W. Denning; George L. Drusano

doi:10.1128/AAC.00488-07

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope, Peter A. Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, Thomas J. Walsh, David W. Denning, George L. Drusano

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

Original language	English (US)
Pages (from-to)	3760-3762
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	51
Issue number	10
DOIs	https://doi.org/10.1128/AAC.00488-07
State	Published - Oct 2007
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00488-07

Cite this

Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., Walsh, T. J., Denning, D. W., & Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing. Antimicrobial agents and chemotherapy, 51(10), 3760-3762. https://doi.org/10.1128/AAC.00488-07

@article{853890703f064e79ae3a140f80a32bc3,

title = "Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing",

abstract = "Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.",

author = "Hope, {William W.} and Warn, {Peter A.} and Andrew Sharp and Paul Reed and Brian Keevil and Arnold Louie and Walsh, {Thomas J.} and Denning, {David W.} and Drusano, {George L.}",

year = "2007",

month = oct,

doi = "10.1128/AAC.00488-07",

language = "English (US)",

volume = "51",

pages = "3760--3762",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis

T2 - A pharmacodynamic rationale for reduced dosing

AU - Hope, William W.

AU - Warn, Peter A.

AU - Sharp, Andrew

AU - Reed, Paul

AU - Keevil, Brian

AU - Louie, Arnold

AU - Walsh, Thomas J.

AU - Denning, David W.

AU - Drusano, George L.

PY - 2007/10

Y1 - 2007/10

N2 - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

AB - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

UR - http://www.scopus.com/inward/record.url?scp=34948813009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948813009&partnerID=8YFLogxK

U2 - 10.1128/AAC.00488-07

DO - 10.1128/AAC.00488-07

M3 - Article

C2 - 17682101

AN - SCOPUS:34948813009

SN - 0066-4804

VL - 51

SP - 3760

EP - 3762

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 10

ER -

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this